TrialStat's EDC Platform Adds Graphical Reporting Features and More
TrialStat (Ottawa, Canada) announces enhancements to its Web-based ClinicalAnalytics 4.0 EDC solution including graphical reporting tools, automated post data entry validation, and optimized study management.
Version 4.0's browser configurable aggregated study reporting now allows users to isolate, retrieve, and view complex data sets, as well as evaluate and compare data sources from multiple study sources within a project. Its integrated post data entry validation automatically validates the accuracy of data across multiple forms and subjects based on a study's configuration and associated data validation rules. And its study management includes improved user permission interfaces, form level permissions, and date time controls.
TrialStat, (866) 416-7828, www.trialstat.com
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.